Sertraline in symptomatic chronic breathlessness: a double blind, randomised trial

Currow, DC; Ekström, M; Louw, S; Hill, J; Fazekas, B; Clark, K; Davidson, PM; McDonald, C; Sajkov, D; McCaffrey, N; Doogue, M; Abernethy, AP; Agar, M

Sertraline in symptomatic chronic breathlessness: a double blind, randomised trial

Currow, DC

Ekström, M Louw, S Hill, J Fazekas, B Clark, K Davidson, PM

McDonald, C Sajkov, D McCaffrey, N Doogue, M Abernethy, AP Agar, M

Permalink

Publication Type:: Journal Article
Citation:: The European respiratory journal, 2019, 53 (1)
Issue Date:: 2019-01-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Accepted Manuscript VersionAdobe PDF (475 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Currow, DC https://orcid.org/0000-0003-1988-1250	en_US
dc.contributor.author	Ekström, M	en_US
dc.contributor.author	Louw, S	en_US
dc.contributor.author	Hill, J	en_US
dc.contributor.author	Fazekas, B	en_US
dc.contributor.author	Clark, K	en_US
dc.contributor.author	Davidson, PM https://orcid.org/0000-0003-2050-1534	en_US
dc.contributor.author	McDonald, C	en_US
dc.contributor.author	Sajkov, D	en_US
dc.contributor.author	McCaffrey, N	en_US
dc.contributor.author	Doogue, M	en_US
dc.contributor.author	Abernethy, AP	en_US
dc.contributor.author	Agar, M https://orcid.org/0000-0002-6756-6119	en_US
dc.date.available	2018-10-03	en_US
dc.date.issued	2019-01-01	en_US
dc.identifier.citation	The European respiratory journal, 2019, 53 (1)	en_US
dc.identifier.uri	http://hdl.handle.net/10453/138894
dc.description.abstract	Copyright ©ERS 2019. Does sertraline provide symptomatic relief for chronic breathlessness in people with advanced disease whose underlying cause(s) are optimally treated?223 participants with chronic breathlessness (modified Medical Research Council breathlessness scale ≥2) who had optimal treatment of underlying cause(s) were randomised 1:1 to sertraline 25-100 mg (titrated upwards over 9 days) or placebo for 4 weeks. The primary outcome was the proportion who had an improvement in intensity of current breathlessness >15% from baseline on a 100-mm visual analogue scale.The proportion of people responding to sertraline was similar to placebo for current breathlessness on days 26-28 (OR 1.00, 95% CI 0.71-1.40) and for other measures of breathlessness. Quality of life in the sertraline arm had a higher likelihood of improving than in the placebo arm over the 4 weeks (OR 0.21, 95% CI 0.01-0.41; p=0.044). No differences in performance status, anxiety and depression, or survival were observed. Adverse event rates were similar between arms.Sertraline does not appear to provide any benefit over placebo in the symptomatic relief of chronic breathlessness in this patient population.	en_US
dc.relation.ispartof	The European respiratory journal	en_US
dc.relation.isbasedon	10.1183/13993003.01270-2018	en_US
dc.rights	info:eu-repo/semantics/openAccess
dc.subject.classification	Respiratory System	en_US
dc.title	Sertraline in symptomatic chronic breathlessness: a double blind, randomised trial	en_US
dc.type	Journal Article
utslib.citation.volume	1	en_US
utslib.citation.volume	53	en_US
utslib.for	1116 Medical Physiology	en_US
utslib.for	11 Medical and Health Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/IMPACCT
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Nursing
utslib.copyright.status	open_access	*
pubs.issue	1	en_US
pubs.publication-status	Published	en_US
pubs.volume	53	en_US

Abstract:

Copyright ©ERS 2019. Does sertraline provide symptomatic relief for chronic breathlessness in people with advanced disease whose underlying cause(s) are optimally treated?223 participants with chronic breathlessness (modified Medical Research Council breathlessness scale ≥2) who had optimal treatment of underlying cause(s) were randomised 1:1 to sertraline 25-100 mg (titrated upwards over 9 days) or placebo for 4 weeks. The primary outcome was the proportion who had an improvement in intensity of current breathlessness >15% from baseline on a 100-mm visual analogue scale.The proportion of people responding to sertraline was similar to placebo for current breathlessness on days 26-28 (OR 1.00, 95% CI 0.71-1.40) and for other measures of breathlessness. Quality of life in the sertraline arm had a higher likelihood of improving than in the placebo arm over the 4 weeks (OR 0.21, 95% CI 0.01-0.41; p=0.044). No differences in performance status, anxiety and depression, or survival were observed. Adverse event rates were similar between arms.Sertraline does not appear to provide any benefit over placebo in the symptomatic relief of chronic breathlessness in this patient population.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/138894